14- ,

2-5% .
2004

7124, 75,4% .

2003
66,7%.

, ( 6,8
6,7 100 . ),



1. (15.0):

(
), 18 .
2.
) (15.3),

24 ;
) (15.4)

- .
32 ;
) (15.5) 8
( )

- .
40 .

, ;



,
,
.

;
;
,
( 8 );
(skip metastasis)
, 30% , 23%

.

, :



,
;



,
;




,

TNM
(6- , 2002 .)
-

0

Tis (Carcinoma in
situ)
1

2

3

4

N
N

N0

N1

0
1

1
1b

1
1b

1
1b

+ :192 , 3 33+ :5-

10% ( 9%)
(EORTC,1982 )
+:
85% 70%,

: 130 60 +()5Fu/mitomicin-C. 2- 30% 12%,

14,9. 9,0 . (ECOG,1990)
: 1- 18%, 5- 6%
(Fisher SA, Brady LW. Esophagus. In: Perez CA, Brady LW, eds. Principles
and practice of radiation oncology,3rd ed.,1998)

56( 8) ,
18-20.
,
(, ,
), 60-70,
4650.

a) ;
b) , 9;
c) , 4